title: Interleukin-25 negatively controls pathogenic responses in the gut.
abstract: Although interleukin-25 (IL-25) has been traditionally considered as a cytokine involved in T helper (Th) 2 cell-associated allergic diseases and host defence against helminthic parasites, recent studies have shown that IL-25 exerts negative effects on the initiation and progression of Th1/Th17-mediated pathologies. This later function of IL-25 is particularly evident at the gut level, where IL-25 could contribute to attenuate tissue-damaging immune responses. These new and exciting pre-clinical observations suggest that therapeutic interventions aimed at enhancing IL-25 activity could be useful in the management of patients with chronic gut inflammation.
authors.affiliation: Dipartimento di Medicina Interna, Università Tor Vergata, Via Montpellier 1, 00133 Roma, Italy.
authors.forename: Eleonora
authors.initials: E
authors.lastname: Franzè
authors.forename: Angelamaria
authors.initials: A
authors.lastname: Rizzo
authors.forename: Roberta
authors.initials: R
authors.lastname: Caruso
authors.forename: Francesco
authors.initials: F
authors.lastname: Pallone
authors.forename: Giovanni
authors.initials: G
authors.lastname: Monteleone
mesh_terms: D000818:Animals; D003093:Colitis, Ulcerative / Q000276:immunology* / Q000628:therapy; D003424:Crohn Disease / Q000276:immunology* / Q000628:therapy; D025461:Feedback, Physiological; D006801:Humans; D018928:Immunity, Mucosal / Q000187:drug effects; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D007167:Immunotherapy; D020381:Interleukin-17 / Q000276:immunology* / Q000494:pharmacology; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D058408:Th1-Th2 Balance / Q000187:drug effects; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology
chemical_list: C486701:IL25 protein, human; D007155:Immunologic Factors; D020381:Interleukin-17